As Donald J. Trump prepares to begin his second presidential administration on January 20, 2025, many Department of Justice (“DOJ”) priorities and policies are likely to change. One new Biden administration initiative that is...more
1/13/2025
/ Corporate Crimes ,
Corporate Misconduct ,
Department of Justice (DOJ) ,
Enforcement Actions ,
False Claims Act (FCA) ,
Fraud ,
Pilot Programs ,
Securities and Exchange Commission (SEC) ,
Whistleblower Awards ,
Whistleblowers ,
White Collar Crimes
In late 2019, Gustav Eyler, the Director of the U.S. Department of Justice’s (“DOJ”) Consumer Protection Branch (“CPB”), cited fraudulent data in clinical research trials for new drugs and medical devices as a topic of “major...more
3/23/2021
/ Clinical Laboratory Testing ,
Clinical Trials ,
Coronavirus/COVID-19 ,
Corruption ,
Criminal Prosecution ,
Department of Justice (DOJ) ,
Enforcement ,
False Statements ,
Food and Drug Administration (FDA) ,
Fraud ,
Medical Devices ,
Medical Research ,
Pharmaceutical Industry ,
Popular ,
Willful Misconduct ,
Wire Fraud